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Introduction {#sec1}
============

Parkinson\'s disease (PD) is a disorder of the CNS that manifests as a progressive degeneration of motor mobility, loss of balance, and tremors. Features of the pathology include loss of dopaminergic neurons in the midbrain and the presence of protein aggregates termed Lewy bodies, composed mainly of α-synuclein, in surviving neurons ([@bib8]). About 10% of cases have a genetic basis, with the most common gene being the leucine-rich repeat kinase 2 (LRRK2) ([@bib35]). The gene product is a 2,527-residue (286 kDa) protein with multiple domains belonging to the ROCO family that is involved in regulation of autophagy, mitochondria, and Golgi dynamics ([@bib32]). The kinase domain, located near the C terminus, phosphorylates itself and other proteins at serine/threonine residues ([@bib12], [@bib35], [@bib37]). Preceding the kinase domain, there is a Ras-like ROC domain (Ras of complex) followed in tandem by a COR domain (C-terminal of Ras). The ROC domain binds nucleotides (GTP/GDP) and is distantly related to the Rab family of small GTPases. The ROC-COR tandem domains regulate LRRK2 activity, and numerous missense mutations have been localized to these regulatory and kinase domains ([@bib15], [@bib30], [@bib46]). In addition to early onset forms of PD associated with autosomal dominant mutations, LRRK2 is also linked to late-onset sporadic cases of PD ([@bib2]).

Insight into LRRK2 functions has progressed significantly with the finding that a subset of small GTPases that include Rab8 and Rab10 are physiological substrates of the enzyme ([@bib37], [@bib42]). Rabs comprise the largest group (∼70 members) of the Ras superfamily, and they cycle between an active GTP bound and inactive GDP form to regulate membrane trafficking in eukaryotic cells ([@bib16]). The nucleotide-bound state of Rabs is regulated by GTPase-activating proteins (GAPs) and GTP/GDP exchange factors (GEFs), and active Rabs migrate to distinct sub-cellular compartments where they recruit cytosolic effector proteins. The "switch" regions of Rabs, termed switch 1 and 2, undergo local conformational changes that enable recruitment of GTP-specific effectors, which subsequently control processes, such as vesicle formation/fusion, motility, and other aspects of cell dynamics ([@bib22]). LRRK2 phosphorylates Rab8a at T72 and Rab10 at T73, conserved threonine residues located on the α-helical switch 2 region. This post-translational modification modulates interactions between Rabs and their binding partners ([@bib37], [@bib36]). For example, it inhibits interaction with Rab GDP dissociation inhibitors (GDIs) and Rabin-8, a GEF for Rab8a ([@bib37]). LRRK2 phosphorylation of Rab8a and Rab10 also promoted interaction with two poorly studied scaffolding proteins termed RILPL1 (Rab interacting lysosomal protein-like 1) and RILPL2 ([@bib36]), that were previously implicated in regulating ciliogenesis ([@bib33]). RILPL1 and RILPL2 belong to the RILP family of effector proteins ([@bib18]). Unlike RILPL1 and RILPL2, RILP was not observed to interact with LRRK2 phosphorylated Rab8a or Rab10 ([@bib36]); however, it is a known effector for Rab7a GTPase ([@bib4]). A recent study has suggested that RILP may bind more strongly to Rab7a phosphorylated at the equivalent site to LRRK2 by the related LRRK1 kinase ([@bib14]). Cellular studies have confirmed that LRRK2 blocks ciliogenesis by phosphorylating Rab8a and Rab10 and promoting RILPL1 interaction ([@bib5]). RILPL1 and RILPL2 are homologous and were shown to interact with LRRK2-phosphorylated Rab8a and Rab10 via a C-terminal phospho-Rab binding domain that encompasses a conserved region of the protein. This region of the protein is also known as the RILP homology domain 2 (RH2) and encompasses residues 291--356 on RILPL1 and residues 130--201 on RILPL2. RILPL1 and RILPL2 also contain an N-terminal RH1 domain that binds to the globular tail domain (GTD) of myosin Va ([@bib25]).

Upstream of the kinase, it has been shown that Rab29 recruits LRRK2 to the Golgi and activates the kinase, leading to an enhanced phosphorylation of substrate Rab GTPases, as well as increased autophosphorylation ([@bib10], [@bib26], [@bib31]). Rab32 is not a target for the kinase but it interacts with LRRK2 and regulates its sub-cellular localization ([@bib40]). These findings place LRRK2 at the center of a Rab signaling cascade that is key to understanding the molecular pathways that underpin PD. Recently, PPM1H has been identified as the phosphatase that counters LRRK2 activity via a phosphatase family small interfering RNA screen ([@bib3]). PPM1H efficiently hydrolyses the phosphate from pRab8a and pRab10 substrates *in vitro* and in cells. Reversible phosphorylation provides a means of tuning the strength of interactions between Rab GTPases and their interacting proteins. Here, we describe the crystal structure of T72 phosphorylated Rab8a(GTP) in complex with a minimal phospho-Rab binding domain of RILPL2 at 1.8 Å resolution. The structure reveals that the phosphothreonine (pT72) is recognized by a conserved arginine from the RILP family of proteins. Moreover, RILPL2-related proteins JIP3 and JIP4 interact with pT73-Rab10 suggesting a general mechanism for phospho-specific recognition of effectors by Rab GTPases.

Results {#sec2}
=======

Overall Structure of the pRab8a:RILPL2 Complex {#sec2.1}
----------------------------------------------

For these studies we utilized a mutant of the globular G-domain of Rab8a (Q67L, residues 1--181) that binds GTP constitutively. Descriptions of the *in vitro* kinase reaction and subsequent purification of pRab8a are described in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. Full-length RILPL2 complexes failed to crystallize, but the phospho-Rab binding domain of RILPL2 (residues 129--165) yielded crystals in complex with pRab8a. This region is the minimal RH2 motif with high sequence similarities to all members of the RILP effector family. Crystals of the complex diffract to 1.8 Å resolution ([Table 1](#tbl1){ref-type="table"}). The complex of pRab8a(GTP):RILPL2 is organized as a heterotetramer in the asymmetric unit ([Figures 1](#fig1){ref-type="fig"}A and 1B), with a central parallel α-helical dimer of the phospho-Rab binding domain of RILPL2 bridging two molecules of pRab8a via hydrophobic and polar interactions ([Figure 1](#fig1){ref-type="fig"}C). As depicted by the domain organization of RILPL1/2 ([Figure 1](#fig1){ref-type="fig"}D), the topology of the complex on Golgi membranes would be consistent with the RH1 domain of RILPL2 (1--106) oriented above the complex in the orientation shown in [Figure 1](#fig1){ref-type="fig"}A to enable interactions with the GTD of MyoVa. Both molecules of pRab8a in the complex have GTP in the nucleotide pocket and their switch 1 and 2 conformations resemble the structure of active Rab8a (PDB: [4lhw](pdb:4lhw){#intref0010}; [@bib13]). Each pRab8a molecule interacts with both α helices of the effector, burying approximately 625 Å^2^ of surface area at each interface. The dual α-helical interactions are restricted to the N-terminal segment of RILPL2. As the coiled coil extends toward the C termini, a single α helix interacts with each Rab monomer by interfacing with switch 1 and strand β2 of the interswitch region ([Figure 1](#fig1){ref-type="fig"}E). The C termini of pRab8a (177--207) and RILPL2 (160--211) would reside proximal to the membrane, as indicated with dashed lines following helix α5 of pRab8a ([Figure 1](#fig1){ref-type="fig"}A). In the ensuing discussions, the acronyms "RL2" and "R8" will be used in superscript format to denote RILPL2 and Rab8a residues, respectively.Table 1Crystallographic Data and Refinement Statistics**Data Collection**BeamlineNECAT APS, 24-ID-EWavelength (Å)0.9792Space groupP 2~1~ 2~1~ 2~1~Cell dimensions a, b, c, (Å)60.333, 71.509, 114.784Resolution (Å)53.41--1.767 (1.83--1.767)Total reflections324,590 (29,329)Unique reflections49,201 (4,719)Completeness (%)99.55 (96.33)\<I/σ\>16.4 (1.69)Multiplicity6.6 (6.2)R~merge~0.06877 (0.9488)R~meas~0.07469 (1.036)R~pim~0.02883 (0.4097)CC~1/2~0.999 (0.649)**Refinement**No. of reflections for R~work~49,193 (4,718)No. of reflections for R~free~2,419 (241)R~work~0.1789 (0.2882)R~free~0.2105 (0.3049)No. of non-hydrogen atoms3,832 Macromolecules3,401 Ligands72 Solvent359 Protein residues416RMSD Bond lengths (Å)0.007 Bond angles (°)0.91Average overall B factor36.54Mean B factors (Å^2^) Protein35.84 Ligand29.72 Water44.53Ramachandran analysis (%) Favored97.24 Allowed2.76PDB:[6rir](pdb:6rir){#intref0140}[^3]Figure 1Structure of pRab8a in Complex with the Phospho-Rab Binding Domain of RILPL2(A) Heterotetrameric assembly of two pRab8a molecules bridged by a central α-helical dimer of the phospho-Rab binding domain of RILPL2 (129--165). The two chains of RILPL2 are in magenta and dark yellow. For pRab8a, switch 1 is shown in blue, switch 2 in red.(B) View of the complex down the 2-fold axis of the heterotetramer, 90° relative to orientation in (A).(C) Stick model of the RH2 domain of RILPL2. Rabs are stripped from the complex in this view, except for short segments of switch 1 and switch 2 (gray sticks).(D) Domain organization of RILPL1/2 showing the RH domains and their interacting partners. The sequence corresponds to RILPL2.(E) Simplified representation of the Rab:RILPL2 interface showing contacts between one molecule of Rab8a and the dimer of RILPL2. Polar interactions are indicated in dotted blue lines. Switch 1 (Sw1) and switch 2 are indicated.(F) Isothermal titration calorimetry analyses of the interactions between pRab8a and the phospho-Rab binding domain of RILPL2. Left, titration of RILPL2 (residues 129--165) into pRab8a(GTP). Right, titration of RILPL2 into Rab8a(GTP).

The affinity of the interaction between pRab8a and the phospho-Rab binding domain (129--165) of RILPL2 was evaluated by isothermal titration calorimetry ([Figure 1](#fig1){ref-type="fig"}F, Left). The experiment revealed a K~d~ = 3.3 μM (±0.5) for the interaction, which indicates a relatively weak affinity that is similar to other physiological Rab:effector complexes ([@bib22]). RILPL2 is a preformed dimer in solution, as indicated by static light scattering coupled to gel filtration chromatography ([Figure S2](#mmc1){ref-type="supplementary-material"}). There were no detectable interactions between non-phosphorylated Rab8a(GTP) and RILPL2 ([Figure 1](#fig1){ref-type="fig"}F, Right).

Phosphorylated Switch 2 of Rab8a Interacts with an "X-cap" Region of RILPL2 {#sec2.2}
---------------------------------------------------------------------------

The N termini of the RILPL2 dimer (N129^RL2^-T134^RL2^) cross over in an extended conformation preceding the first α-helical turn, forming an X-shaped cap (X-cap) over the coiled coil ([Figures 2](#fig2){ref-type="fig"}A and 2B). The X-cap facilitates interactions of both monomers of RILPL2 with a single phosphorylated switch 2 of pRab8a. This X-cap contains two conserved arginines (R130^RL2^ and R132^RL2^) that previous mutagenesis analysis showed were required for interaction with pRab8a ([@bib36]). Intimate contacts within the X-cap include reciprocal backbone hydrogen bonds between residues R132^RL2^-Phe133^RL2^ that resemble a short antiparallel β sheet ([Figure 2](#fig2){ref-type="fig"}B). The phosphate moiety from pT72 interacts with the guanidino group (NH1/NH2) of R132^RL2^ on both sides of the symmetric complex, with O/N distances between 2.5 and 2.9 Å ([Figure 2](#fig2){ref-type="fig"}C). In contrast to these direct electrostatic and hydrogen-bonding interactions, the side chain of R130^RL2^ is more distant from pT72 (\>6 Å). An electrostatic surface map of RILPL2 reveals the strongly positive charges at the X-cap that enable recognition of pRab8a ([Figure 2](#fig2){ref-type="fig"}D). In addition to electrostatic contacts, the X-cap residue F133^RL2^ contributes to a complementary hydrophobic interface with F70^R8^ and I73^R8^ from switch 2. The side chain of T134^RL2^ acts as a capping residue by nucleating the α helix via a hydrogen bond (3.2 Å) to the backbone NH of E137^RL2^. Therefore, the term X-cap is appropriate for this region of RILPL2.Figure 2Structural Details of pT72 Recognition by the X-cap of RILPL2(A) View of an interface between pRab8a and the dimer of RILPL2.(B) Stick model of the interactions at the X-cap of RILPL2.(C) Electron density (2F~o~ − F~c~, 1.2σ) at the site of pT72 (chain A) binding to R132^RL2^ (chain D, magenta). The side chain of L135^RL2^ from chain C of RILPL2 lies within van der Waals contact (4 Å) of the β-branched methyl group of pT72.(D) Electrostatic surface rendering of the X-cap. Blue is positive and red is negative, while switch 1 and 2 of pRab8a are ribbons with key residues represented as sticks.

Mutational Analyses of the Binding Interface {#sec2.3}
--------------------------------------------

The contribution of RILPL2 residues to complex formation with pRab8a was evaluated by mutagenesis. LRRK2-phosphorylated Rab8a was subjected to co-immunoprecipitation studies in cells using wild-type and mutant forms of full-length RILPL2. For these studies a pathogenic LRRK2\[R1441G\] mutant was overexpressed to ensure maximal phosphorylation of Rab8a. We also treated cells with and without a potent and selective LRRK2 inhibitor termed MLi-2 ([@bib9]) for 90 min to induce dephosphorylation of Rab8a and, therefore, block association with RILPL2 ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}). These results revealed that all mutations of R132^RL2^, which directly interacts with pT72, abolished the interaction with pRab8a in cells. The exquisite specificity of this contact is reflected by the R132K^RL2^ mutation, which was sufficient to abolish the interaction ([Figure 3](#fig3){ref-type="fig"}A). Mutation of K149^RL2^---which forms a salt bridge with D44^R8^ (switch 1)---also abolishes the interaction between RILPL2 and pRab8a. This interaction, as well as hydrophobic packing of I41^R8^ against the RILPL2 α-helical dimer, presumably encodes GTP-dependent switch 1 specificity. Modest effects were observed with mutations of R139^RL2^ and L135^RL2^, which form contacts with switch 2 adjacent to the R132^RL2^:pT72 interaction. L135 packs against the β-branched methyl substituent of pT72, while R139 forms a hydrogen bond with the backbone carbonyl oxygen of pT72 ([Figures 2](#fig2){ref-type="fig"}A and 2C).Figure 3Mutational Analyses Reveal Hotspots of pRab8a:RILPL2 Interactions(A) HEK293 cells were transiently transfected with constructs expressing Flag-LRRK2\[R1441G\], HA-Rab8a and WT or mutant RILPL2-GFP. At 48 h post transfection, cells were treated with ±500 nM MLi-2 for 90 min and then lysed. Upper panel, labeled IP:GFP: RILPL2-GFP was immunoprecipitated using GFP binder Sepharose and immunoprecipitates evaluated by immunoblotting with the indicated antibodies. Immunoblots were developed using the LI-COR Odyssey CLx western blot imaging system with the indicated antibodies at 0.5--1 μg/mL concentration. Lower panel, labeled input: 10 μg whole-cell lysate was subjected to LI-COR immunoblot analysis. Each lane represents cell extract obtained from a different dish of cells. Similar results were obtained in two separate experiments. (B) Same as A, but HEK293 cells were transiently transfected with WT or mutant HA-Rab8a as well as Flag-LRRK2\[R1441G\] and RILPL2-GFP WT. At 48 h post transfection, cells were treated with ±500 nM MLi-2 for 90 min and then lysed. RILPL2-GFP was immunoprecipitated using GFP binder Sepharose and as in (A), immunoprecipitates and input were evaluated by immunoblotting with the indicated antibodies. Each lane represents cell extract obtained from a different dish of cells. Similar results were obtained in two separate experiments.(C) Sequence alignment of the first α helix (α1) of the RILP family RH2 domains. Residues corresponding to the second α helix (α2) of RILP are not shown. Red circles are hotspots for the interactions where mutations severely reduce affinity between pRab8a and RILPL2. Blue circles indicate residues that are tolerant to mutations. The α-helical secondary structure above the alignment corresponds to RILPL2.

One apparent inconsistency between the structure and the mutagenesis experiments is the contribution of R130^RL2^ toward complex formation. Mutational studies reveal that R130Q^RL2^ ([Figure 3](#fig3){ref-type="fig"}A), as well as R130K^RL2^, R130E^RL2^, and R130A^RL2^ ([Figure S3](#mmc1){ref-type="supplementary-material"}), severely compromise interactions with pRab8a, although to a lesser extent than R132^RL2^ mutants. As previously mentioned, the side chain of R130^RL2^ lies more than 6 Å away from pT72. There are two mechanisms by which the guanidino group of R130^RL2^ could contribute to complex formation. One is through long-range electrostatic interactions with pT72. A second mechanism may be an indirect stabilization of the key R132^RL2^:pT72 contacts through stacking interactions with the side chain of R132^RL2^. More detailed analyses of a full-length construct of RILPL2 and its affinity toward pRab8a is described below.

In addition to RILPL2, key residues in switch 1 and the N terminus of pRab8a were mutated to evaluate contributions to complex formation ([Figure 3](#fig3){ref-type="fig"}B). Most mutations in Rab8a tested likely disrupted protein stability, binding with other key interactors or phosphorylation by LRRK2 and, therefore, it was not possible to reliably evaluate the role of these residues in RILPL2 interaction *in vivo*. However, Rab8a mutations T4A^R8^ and K58A^R8^ were still phosphorylated by LRRK2 and were able to bind RILPL2, suggesting that these residues are not critical for this interaction.

The hotspots for pRab8a:RILPL2 interactions, as gleaned from cellular interactions with RILPL2 mutants, are shown with circles above the sequences of RILP family proteins ([Figure 3](#fig3){ref-type="fig"}C). The red circles denote essential residues for recognition of pRab8a(GTP) and are mostly conserved in the phospho-Rab binding domains. Arg139^RL2^ mutations have modest effects on Rab8a recognition ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}), and are not conserved (blue circle). Pro131^RL2^ is variable in this family and the mutant Pro131A^RL2^ does not affect binding, suggesting that sequence variability is possible within the X-cap.

GTP Dependency of the Interaction between pRab8a and RILPL2 {#sec2.4}
-----------------------------------------------------------

The GTP dependency of pRab8a interactions with full-length RILPL2 were investigated using *in vitro* pull-downs ([Figure 4](#fig4){ref-type="fig"}A). The interaction with RILPL2 *in vitro* is dependent on both the GTP conformation and phosphorylated T72 for Rab8a. Non-phosphorylated Rab8a and pRab8a(GDP) did not interact measurably with RILPL2.Figure 4Evidence that RILPL2 Binds to the GTP Bound Conformation of Phosphorylated Rab8a in Cells(A) Direct *in vitro* pull-downs were performed using purified His~6~-tagged RILPL2 (full length) as bait and untagged Rab8a as prey. Rab8a species were either non-phosphorylated (Rab8a) or phosphorylated (pRab8a). The GTP forms were stabilized via the Q67L mutation in switch 2. The GDP form of Rab8a was prepared by *in vitro* exchange using wild-type (WT) Rab8a before the phosphorylation reaction to generate pRab8a(GDP). Protein concentrations were 10 μM for bait and prey, inputs are 2 μg; n ≥ 3, Coomassie stain for visualization. Dotted lines emphasize that only pRab8a(GTP) binds to RILPL2.(B) HEK293 cells were transiently transfected with constructs expressing the indicated components. 24 h post transfection, cells were treated with ±100 nM MLi-2 for 90 min and then lysed. Upper panel, labeled IP:GFP: RILPL2-GFP was immunoprecipitated using GFP binder Sepharose and immunoprecipitates evaluated by immunoblotting with the indicated antibodies. Immunoblots were developed using the LI-COR Odyssey CLx western blot imaging system with the indicated antibodies at 0.5--1 μg/mL concentration. Lower panel, labeled input: 10 μg whole-cell lysate was subjected to LI-COR immunoblot analysis. Each lane represents cell extract obtained from a different dish of cells. Similar results were obtained in two separate experiments.

To further investigate the GTP dependency in cells, we co-expressed RILPL2 with either wild-type Rab8a, Rab8a\[Q67L\] (GTP trapped conformation) or Rab8a\[T22N\] (GDP bound conformation) in the presence of pathogenic LRRK2\[Y1699C\] to induce maximal Rab8a phosphorylation ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). For these experiments, cells were treated ± LRRK2 MLi-2 inhibitor and phosphorylation of wild-type and mutant Rab8a was assessed in cell extracts as well as RILPL2 immunoprecipitates. Strikingly, this revealed that both cell lysates and immunoprecipitates of the pRab8a\[Q67L\] GTP locked mutant, MLi-2 failed to induce dephosphorylation of Rab8a over a 90-min period ([Figure 4](#fig4){ref-type="fig"}B). As mentioned previously, PPM1H has been identified as the phosphatase that dephosphorylates Rab GTPases ([@bib3]). One interpretation of this observation is that the pRab8a\[Q67L\] GTP locked conformation remains stably associated with RILPL2 over this period and is thus protected from PPM1H. However, it cannot be excluded that PPM1H acts exclusively on pRab8a(GDP) in the cytosol, although *in vitro* studies demonstrated that PPM1H dephosphorylated pRab8a(GTP) and pRab8a(GDP) with similar efficiency ([@bib3]). In comparison, MLi-2 treatment induced significant dephosphorylation of wild-type Rab8a that is presumably interconverting between the GTP and GDP conformation ([Figure 4](#fig4){ref-type="fig"}B). The GDP-locked conformation of Rab8a\[T22N\] was expressed at much lower levels in cell than wild-type or Rab8a\[Q67L\] ([Figure S4](#mmc1){ref-type="supplementary-material"}). Nevertheless, no association of RILPL2 with Rab8a\[T22N\] was observed. Furthermore, phosphorylation of Rab8a\[T22N\] was not observed which is consistent with the GTP bound conformation being regulated by LRRK2.

Binding of pRab8a to Full-Length RILPL2 Is Enhanced by MyoVa {#sec2.5}
------------------------------------------------------------

Relative to the isolated RH2 domain, all observed interactions *in vitro* between pRab8a and full-length RILPL2 were weak and unsuitable for isothermal titration calorimetry (e.g., [Figure 4](#fig4){ref-type="fig"}A). However, in the presence of the GTD of MyoVa, we observed a small but significant enhancement in affinity between pRab8a and RILPL2. Therefore, we utilized pull-down assays to characterize pRab8a:RILPL2 complex formation in the presence of MyoVa ([Figures 5](#fig5){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). The binary interactions between MyoVa and mouse RILPL2 have been measured previously (K~d~ = 0.3 μM; [@bib41]), and are 10-fold stronger than pRab8a interactions with the RH2 domain. In the presence of MyoVa, there is a clear increase in affinity between pRab8a and full-length RILPL2 ([Figure 5](#fig5){ref-type="fig"}A). This interaction is dependent on phosphorylated T72, since Rab8a(GTP) does not interact with the RILPL2:MyoVa complex. There are no observable interactions between pRab8a/Rab8a and the GTD of MyoVa ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}).Figure 5MyoVa Interactions with the RH1 Domain Enhance the Affinity of RILPL2 to pRab8a(A) Pull-downs of (p)Rab8a and RILPL2 in the presence of MyoVa(GTD). Input proteins are in the upper left panel, while duplicate pull-downs are shown to the right. Phosphorylated Rab8a (pRab8a) is highlighted in the pull-down lanes with red (+) labels. Bait and prey proteins were used at 2.5 μM.(B) Control experiment showing that no interactions are observed between His~6~-tagged MyoVa and pRab8a/Rab8a.(C) Quantification of densitometry readings of pRab8a pull-downs from three independent experiments (p \< 0.005).(D) Modeling of full-length RILPL2 using ribbons and electrostatic surfaces. The RH1 domain of mouse RILPL2 was connected to the RH2 domain of human RILPL2. Residue numbers correspond to the human protein.

The pull-downs were quantified to show the relative increase in binding of pRab8a:RILPL2 in the presence of MyoVa ([Figure 5](#fig5){ref-type="fig"}C). These data suggest that MyoVa(GTD) binding to the RH1 domain of RILPL2 enhances the affinity between the RH2 domain and pRab8a. A model of RILPL2 was built using the structure of the mouse RH1 domain (PDB: [4kp3](pdb:4kp3){#intref0015}) together with the human RH1 domain ([Figure 5](#fig5){ref-type="fig"}D). The side-by-side ribbon and electrostatic surface model shows that the two regions have complementary charges separated by a 20-residue flexible linker. In the absence of MyoVa, the RH1/RH2 domains of RILPL2 could interact in *cis*, thereby sterically blocking the X-cap and reducing the affinity of RH2 for pRab8a.

JIP3/4 Bind to LRRK2-Phosphorylated Rab10 {#sec2.6}
-----------------------------------------

Sequence comparisons suggest that two other scaffolding proteins previously implicated in JNK signaling, namely JIP3 (gene *MAPK8IP3*; [@bib20]) and JIP4 (gene *SPAG9*; [@bib21]), likely possess a phospho-Rab binding domain. These proteins have key residues equivalent to R130^RL2^, R132^RL2^, and K149^RL2^ in their RH2 domain ([Figure 3](#fig3){ref-type="fig"}C). We, therefore, tested whether full-length JIP3 or JIP4 would bind to LRRK2-phosphorylated Rab8a or Rab10 in cells employing the co-expression assay utilized above to assess interaction of pRab8a with RILPL2 ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}). These results revealed that both JIP3 and JIP4 specifically associated with LRRK2-phosphorylated Rab10. Addition of Mli-2 ablated interaction of JIP3 and JIP4 with Rab10 consistent with the interaction being phosphorylation dependent ([Figure 6](#fig6){ref-type="fig"}A). In contrast, a weak interaction just above background was observed between Rab8a and JIP3/4, which was not dependent upon phosphorylation by LRRK2 ([Figure S6](#mmc1){ref-type="supplementary-material"}). This emphasizes that phospho-Rab binding domains are likely to display selectivity for different phosphorylated Rab proteins. Further work is required to identify which sets of phospho-Rab proteins interact with JIP3/4 and how these complexes regulate cytoskeletal dynamics through the microtubule network ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Evidence that JIP3 and JIP4 Bind to LRRK2-Phosphorylated Rab10 in Cells(A) HEK293 cells were transiently transfected with constructs expressing the indicated components. At 24 h post transfection, cells were treated with ±100 nM MLi-2 for 90 min and then lysed. Upper panel, labeled IP:GFP: RILPL2-GFP, JIP3-GFP, JIP4-GFP were immunoprecipitated using GFP binder Sepharose and immunoprecipitates evaluated by immunoblotting with the indicated antibodies. Immunoblots were developed using the LI-COR Odyssey CLx western blot imaging system with the indicated antibodies at 0.5--1 μg/mL concentration. Lower panel, labeled input: 10 μg whole-cell lysate was subjected to LI-COR immunoblot analysis. Each lane represents cell extract obtained from a different dish of cells. Similar results were obtained in two separate experiments.(B) Domain organization of JIP3 and JIP4. Sequence numbers correspond to JIP3, the interacting partners are shown above the cartoon, and p150^G^ refers to p150^Glued^. The figure is adapted from the recent structure of the RH1-LZI domain of JIP3 ([@bib39]). KHC, kinesin heavy chain; KLC, kinesin light chain; DLIC, dynein light intermediate chain.

Discussion {#sec3}
==========

The structure of the Rab binding domain of RILP bound to Rab7 has been determined previously ([Figure 7](#fig7){ref-type="fig"}A) ([@bib45]). Similar to RILPL2, the effector forms a parallel coiled coil that binds two Rab7 molecules as a heterotetrameric complex. RILP does not have an X-cap at the N terminus---the first few residues in the structure beginning at Cys241 are disordered until the start of the core helix at Glu246 ([Figures 7](#fig7){ref-type="fig"}A and 7B). Following helix α1 of the Rab binding domain of RILP, a loop brings a second antiparallel helix α2 back toward the α1 dimer and is stabilized by hydrophobic interactions. Helix α2 is unlikely to be conserved in RILPL1/2 given a string of glycine and proline residues in these proteins following helix α1, which would be disruptive to secondary structures ([Figure 3](#fig3){ref-type="fig"}C). Interestingly, LRRK1 phosphorylation of Rab7 at Ser72 (switch 2) has recently been shown to promote interactions with RILP ([@bib14]). The RILP construct used for recombinant expression begins at C241 and the PDB file (PDB: [1yhn](pdb:1yhn){#intref0020}) for the complex RILP:Rab7 contains the coordinates for RILP beginning at S244 (T134^RL2^). It is possible that an X-cap could form and bind to pSer72 (Rab7) given a modest extension of the RILP polypeptide toward the N terminus to stabilize backbone antiparallel hydrogen bonds. Although RILP lacks a positive residue (Q240), the structure of pRab8a:RILPL2 reveals that Arg130^RL2^ is distant from pThr72 and may be tolerated as a glutamine within a possible X-cap in the RILP:pRab7 complex.Figure 7Structural Comparisons of Rab:Effector Complexes(A) Structure of Rab7 in complex with the Rab binding domain of RILP.(B) Superposition of RILPL2 onto a single binding interface of Rab7:RILP, showing conservation of the α-helical coiled coil. The figure is rotated 90° along the horizontal axis, relative to (A).(C) Structure of Rab8a in complex with OCRL1. The dashed circle denotes the region that sterically clashes with pT72 of pRab8a.(D) Close-up view of the switch 2 region denoted by the dashed circle. Here, pRab8a (red) from the complex with RILPL2 is superimposed onto the structure of Rab8a (gray) in complex with OCRL1. The distances between the methyl groups from the β-branched sidechains of pT72 and Ile71 are shown to highlight the steric clashes.

Unphosphorylated Rab8a is a promiscuous small GTPase and its structures in complex with effectors OCRL1 and MICAL have also been determined. The inositol-5-phosphatase OCRL1 is recruited to Rab8a membranes and regulates aspects of endosomal/Golgi trafficking ([@bib29]). Inherited X-linked mutations in OCRL1 lead to oculocerebrorenal syndrome of Lowe, which is associated with intellectual disability, cataracts, and renal dysfunction. Pull-downs using endogenous and hemagglutinin-tagged Rab8a reveal that OCRL1 does not bind to pRab8a ([@bib36]). Superposition of the Rab8a:OCRL1 onto the pRaba:RILPL2 complex reveals a steric clash of non-hydrogen atoms between switch 2 and OCRL1 ([Figures 7](#fig7){ref-type="fig"}C and 7D). Switch 2 phosphorylation also disrupts interactions between Rab8a and GDI as well as Rabin8, a GEF for Rab8a ([@bib37]). Along with GAPs, these Rab modulators interact with a broad segment of the switch 1/2 interface and would clash with pT72. In contrast to OCRL1, the effector MICAL can be docked onto pRab8a without steric problems (data not shown). Parallel coiled coils as Rab binding motifs are commonly exploited by effectors for membrane trafficking ([@bib22]). However, the RILPL2-RH2 motif described here adopts a unique X-cap structure that resembles a short antiparallel β sheet at the N terminus of the coiled coil. The conformation enables positioning of Arg residues that recognize the phosphate on switch 2. The X-cap is likely a conserved feature among the RILP and JIP family of effector proteins.

A model for LRRK2 control of Rab trafficking is shown in [Figure 8](#fig8){ref-type="fig"}. Recent *in vitro* and cellular data are consistent with active Rab29(GTP) recruitment of the effector LRRK2 onto membranes where it phosphorylates substrates, such as Rab8a ([@bib11], [@bib28]). The post-translational modification is situated at the edge of the switch/interswitch region of pRab8a and facilitates tuning of the strength of interacting proteins, including effectors, GAPs, GEFs, and GDI. The phospho-specific effector, RILPL2, is recruited onto membranes possibly as a preformed complex with MyoVa. Autosomal dominant variants of LRRK2 enhance the levels of pRab10 up to a maximum of 4% of total Rab10 in cells, which is a modest 2- to 4-fold increase over basal phosphorylation ([@bib17], [@bib19]). The effects arising from a small change in LRRK2-phosphorylated Rabs may be amplified through several mechanisms. One is the inability of Rabs to interact with GAPs, thereby prolonging the lifetime of pRabs on membranes. A second mechanism is recruitment of phospho-specific RILPL1/2 at the expense of other effectors, such as OCRL1. Here, we demonstrate that MyoVa enhances the affinity between pRab8a and RILPL2. In addition, a region of MyoVa encoded by exon D, ahead of the C-terminal GTD, also interacts directly with Rab8a and Rab10 ([@bib24]). Finally, the ternary complex of pRab8a:RILPL2:MyoVa may be resistant to PPM1H-mediated hydrolysis of pT72. Together these factors could partly explain how LRRK2 directs pRab8a/10 toward RILPL1/2-associated ciliary trafficking pathways.Figure 8Model for the Control of Rab8a Functions by LRRK2Rab29 recruits LRRK2 to membranes and Rab8a is subsequently phosphorylated by LRRK2. RILPL2 is then recruited to membranes by pRab8a via the X-cap. RILPL2 is an adaptor that links pRab8a to the GTD of MyoVa. The structure of the mouse complex of RILPL2 with myosin was used to generate this figure (PDB: [4kp3](pdb:4kp3){#intref0135}; [@bib41]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit anti LRRK2 N-termUniversity of DundeeUDD3Rabbit anti GFPChromotekPABG1Rabbit anti GFPCell Signaling Technology\#2956Rat anti HAMerck3F10Rabbit anti-pT72-Rab8aAbcamMJF-R20; ab231706Mouse anti LRRK2 C-termNeuroMABN241A/34; [AB_10675136](nif-antibody:AB_10675136){#intref0025}Mouse anti TubulinCell Signaling Technology3873SMouse anti GAPDHSanta Cruz Biotechnologysc-32233Goat anti-Rabbit IRDye 800CWLicor925-32211Goat anti-Mouse IRDye 800CWLicor926-32210Goat anti-Rat IRDye 680LTLicor925-68029Goat anti-mouse IRDye 680LTLicor926-68020Goat anti-Rat IgG HRP conjugatedThermo Fisher Scientific\#31470**Bacterial and Viral Strains**E. coli BL21 (DE3)New England BiolabsC2527E. coli DH5αNew England BiolabsC2987**Chemicals, Peptides, and Recombinant Proteins**His~6~-RILPL2 residue 129-165GenscriptN/AGDPSigma AldrichG7127ATPSigma AldrichA2383MIL-2 LRRK2 inhinbitorMRC PPU Reagents ServicesN/AGST-MST3MRC PPU Reagents ServicesDU30889Polyethylenimine PEIPolysciences23966αGFP binder sepharoseMRC PPU Reagents ServicesN/APhosTag reagentMRC PPU Reagents ServicesN/ANi-agarose fast flowGE Healthcare17531802**Critical Commercial Assays**JCSG-plus crystallography screenMolecular DimensionsMD1-37PACT premier crystallography screenMolecular DimensionsMD1-29Isolate II Miniprep KitBiolineBIO-52057**Deposited Data**pRab8a:RILPL2 complexThis studyPDB: [6RIR](pdb:6RIR){#intref0030}Rab7:RILP complex[@bib45]PDB: [1YHN](pdb:1YHN){#intref0035}Strcture of Rab8a:OCRL1 complex[@bib48]PDB: [3QBT](pdb:3QBT){#intref0040}MyosinVa GTD:RILPL2 complex[@bib41]PDB: [4KP3](pdb:4KP3){#intref0045}**Experimental Models: Cell Lines**HEK293ATCCCRL-1573**Oligonucleotides**Rab8a mutagenesis primer for GG GAT ACC GCG GGT [CAG]{.ul} GAA CGT TTT CGT ACThis studyN/ARab8a mutagenesis primer rev GT ACG AAA ACG TTC [CTG]{.ul} ACC CGC GGT ATC CCThis studyN/A**Recombinant DNA**pET28a(+)-Rab8a~1-181~Q67LGenscriptN/ApET28a(+)-Rab8a~1-181~WTThis studyN/ApET15b-RILPL2GenscriptN/ApET28a(+)-MyosinVa GTDGenscriptN/ApCVM5 HA-emptyMRC PPU Reagents ServicesDU49303pcDNA5 GFP-emptyMRC PPU Reagents ServicesDU13156pCMV Flag-LRRK2 R1441GMRC PPU Reagents ServicesDU13077pCMV Flag-LRRK2 Y1699CMRC PPU Reagents ServicesDU1316pCMV HA-Rab8a WTMRC PPU Reagents ServicesDU35414pCMV HA-Rab10 WTMRC PPU Reagents ServicesDU44250pcDNA5D FRT/TO RILPL2-GFP WTMRC PPU Reagents ServicesDU27481pcDNA5D FRT/TO RILPL2-GFP R130KMRC PPU Reagents ServicesDU68258pcDNA5D FRT/TO RILPL2-GFP R130AMRC PPU Reagents ServicesDU68022pcDNA5D FRT/TO RILPL2-GFP R130QMRC PPU Reagents ServicesDU27521pcDNA5D FRT/TO RILPL2-GFP R130EMRC PPU Reagents ServicesDU27520pcDNA5D FRT/TO RILPL2-GFP P131AMRC PPU Reagents ServicesDU68030pcDNA5D FRT/TO RILPL2-GFP P131CMRC PPU Reagents ServicesDU68031pcDNA5D FRT/TO RILPL2-GFP P131KMRC PPU Reagents ServicesDU68256pcDNA5D FRT/TO RILPL2-GFP P131RMRC PPU Reagents ServicesDU68257pcDNA5D FRT/TO RILPL2-GFP R132KMRC PPU Reagents ServicesDU68023pcDNA5D FRT/TO RILPL2-GFP R132AMRC PPU Reagents ServicesDU67110pcDNA5D FRT/TO RILPL2-GFP R132QMRC PPU Reagents ServicesDU68037pcDNA5D FRT/TO RILPL2-GFP R132EMRC PPU Reagents ServicesDU27522pcDNA5D FRT/TO RILPL2-GFP F133AMRC PPU Reagents ServicesDU68033pcDNA5D FRT/TO RILPL2-GFP L135AMRC PPU Reagents ServicesDU68032pcDNA5D FRT/TO RILPL2-GFP R139AMRC PPU Reagents ServicesDU68025pcDNA5D FRT/TO RILPL2-GFP R139QMRC PPU Reagents ServicesDU68024pcDNA5D FRT/TO RILPL2-GFP R139EMRC PPU Reagents ServicesDU68026pcDNA5D FRT/TO RILPL2-GFP K149AMRC PPU Reagents ServicesDU68029pcDNA5D FRT/TO RILPL2-GFP K149QMRC PPU Reagents ServicesDU68027pcDNA5D FRT/TO RILPL2-GFP K149EMRC PPU Reagents ServicesDU68028pcDNA5D FRT/TO RILPL2-GFP E157AMRC PPU Reagents ServicesDU68036pcDNA5D FRT/TO RILPL2-GFP E157QMRC PPU Reagents ServicesDU68034pcDNA5D FRT/TO RILPL2-GFP E157KMRC PPU Reagents ServicesDU68035pCMV HA-Rab8a Q67LMRC PPU Reagents ServicesDU39393pCMV HA-Rab8a T22NMRC PPU Reagents ServicesDU39392pCMV5 HA-Rab8a T4AMRC PPU Reagents ServicesDU68045pCMV5 HA-Rab8a D44AMRC PPU Reagents ServicesDU68041pCMV5 HA-Rab8a D44NMRC PPU Reagents ServicesDU68039pCMV5 HA-Rab8a D44KMRC PPU Reagents ServicesDU68040pCMV5 HA-Rab8a K58AMRC PPU Reagents ServicesDU68044pCMV5 HA-Rab8a K58QMRC PPU Reagents ServicesDU68042pCMV5 HA-Rab8a K58EMRC PPU Reagents ServicesDU68043pcDNA5D FRT/TO JIP3-GFPMRC PPU Reagents ServicesDU27721pcDNA5D FRT/TO JIP4-GFPMRC PPU Reagents ServicesDU27684pcDNA5D FRT/TO RILPL1-GFPMRC PPU Reagents ServicesDU27305pCVM5 HA-emptyMRC PPU Reagents ServicesDU49303**Software and Algorithms**Phenix[@bib50]<https://www.phenix-online.org/>Coot[@bib7]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>CCP4i[@bib23], [@bib44]<https://www.ccp4.ac.uk/ccp4i_main.php>PyMolSchrödinger, LLC<https://pymol.org>ImageJ (Fiji)[@bib34]<https://imagej.nih.gov/ij/>XDS[@bib49]<http://xds.mpimf-heidelberg.mpg.de/>Aimless[@bib47]<http://www.ccp4.ac.uk/html/aimless.html>Phaser[@bib27]<http://www.ccp4.ac.uk/html/phaser.html>**Other**Superdex 75 (16/60)GE Healthcare28-9893-33Superdex 200 (16/60)GE Healthcare28-9893-35Superdex 75 (10/300)GE Healthcare17-5174-01Superdex 200 (10/300)GE Healthcare17-5175-01MonoS 5/50 GLGE Healthcare17-5168-01PD10 columnGE Healthcare17-0851-01ITC-200 instrumentMalvern PanalyticalN/AminiDAWN system SLS instrumentWyatt CorpN/AOptilab rEX refractometerWyatt CorpN/AZORBAX 300SB-C18 HPLC columnAgilentN/A

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact, Amir Khan (<Amir.Khan@tcd.ie>). This study did not generate new unique agents.

Method Details {#sec4.3}
--------------

### Protein Expression and Purification {#sec4.3.1}

The cDNA for Rab8a (residues 1-181, Q67L) lacking the flexible C-terminal tail was ordered from Genscript in a codon-optimized form to enable *E*.*coli* expression. The cDNA was cloned into pET28a at the NdeI/BamH1 sites for both of these constructs. The Rab8a *wildtype* (WT) construct was made by site directed mutagenesis using the following primers: 5'-GG GAT ACC GCG GGT [CAG]{.ul} GAA CGT TTT CGT AC-3' (for) and: 5'-GT ACG AAA ACG TTC [CTG]{.ul} ACC CGC GGT ATC CC-3' (rev). Expression was carried out in 2xYT Broth supplemented with 34 μg/ml kanamycin (FORMEDIUM™) at 37°C. At an OD~600~ of 0.7 the culture was induced with 0.5 mM IPTG (FORMEDIUM™), after which cells were grown for a further 4 hours at 37°C or 18°C overnight. Cells were harvested by centrifugation and the pellets were resuspended in His-tag extraction buffer (20 mM Tris-HCl, 300 mM NaCl, 5 mM MgCl~2~, 20 mM imidazole and 10 mM β-mercaptoethanol, pH 8.0) along with 0.5 mM PMSF protease inhibitor (Sigma). Cells were lysed by sonication and the cell lysate was centrifuged at 26,000 x *g* for 45 minutes at 4°C to remove cellular debris. The supernatants were filtered and loaded onto a nickel agarose resin (QIAGEN). The resin was washed with a 10-fold excess of extraction buffer and 5-fold excess wash buffer (extraction buffer supplemented with 40 mM Imidazole). The protein was eluted using extraction buffer supplemented with 200 mM imidazole.

Removal of the His~6~-tag (Rab8a) was performed by overnight incubation at 4°C with thrombin (GE Healthcare), followed by a second Ni^2+^-agarose column. The 'flow-through' fractions were collected, while the uncut proteins remained on the resin. Soluble aggregates were eliminated by running the sample through a Superdex 75 (16/60) gel filtration column (GE Healthcare) equilibrated in column buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, pH 7.5). A peptide corresponding to residues 129-165 of RILPL2 was synthesized with an N-terminal hexahistidine tag (His~6~-RILPL2, Genscript). The peptide was solubilized in matching buffer with Rab (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, pH 7.5) prior to crystallization trials and calorimetry.

The cDNA for full-length RILPL2 (1-211) and the GTD of myosin Va (1462-1853), optimized for E.coli expression, were obtained from Genscript. The cDNAs were each synthesized with a 5' NdeI extension and a 3' extension comprising 2xSTOP codons (TAA-TGA) followed by a BamH1 site. The cDNA for RILPL2 was subcloned into the Nde/Bam site of pET15b, while the cDNA for MyoVa(GTD) was subcloned into the identical site in pET28b. Expression and purification of these proteins were performed as described for Rab8a above, except that the polyhistidine tag was not removed from RILPL2 for the pulldown experiment.

### Rab8a Nucleotide Exchange {#sec4.3.2}

For the pulldown with full-length RILPL2, nucleotide exchange was performed using purified WT Rab8a incubated in 10 mM EDTA for 10 minutes at room temperature in the presence of 10X molar excess GDP. The exchange was terminated by addition of 15 mM MgCl~2~ and excess nucleotides were removed by running samples through a PD10 column (GE healthcare), or by immediate gel filtration chromatography. To verify successful exchange, 100 μL the protein (\>1mg/mL) was boiled for 10 min at 95°C to denature the protein and release the nucleotide, followed by centrifugation for 30 min 16,000 x *g*, 4°C to remove precipitated protein. The supernatant was mixed with running buffer (100 mM potassium phosphate, 8 mM thiobarbituric acid, pH 6.5) at a 1:1 ratio. The samples were loaded on an Acquity Ultra Performance system (Waters Corporation, Milford, MA, USA; or Varian 920 LC machine, Agilent, Stockport, UK) equipped with a ZORBAX 300SB-C18 column (Agilent, Stockport, UK). Elution profiles of GMP, GDP, GTP (Sigma Aldrich) and GppNHp (Jena Bioscience, Germany) were subjected to HPLC and compared with Rab8a. The nucleotide state of Rab8a(Q67L) was confirmed to be GTP-bound using the analytical HPLC strategy.

### *In Vitro* Kinase Assays {#sec4.3.3}

It has recently been shown that the MST3 kinase can specifically and efficiently phosphorylate Rab8a at Thr72 *in vitro (*[@bib38]). As MST3 is much easier to express than LRRK2, we decided to phosphorylate Rab8a at T72 using recombinant MST3. For comparison of Rab8a phosphorylation by LRRK2 and MST3, kinase assays were performed with shaking at 30^o^C for 3h with molar concentrations as indicated of 970-end length LRRK2 WT or G2019S (PV4873 and PV4882 respectively, ThermoFisher) or GST-MST3 (supplied by MRC Reagents and Services, DU30889) and 2 μM of Rab8a 1-181 Q67L or Q67L+T72E as a negative control. The kinase reaction buffer is 50 mM Tris-HCl pH 7.5, 10 mM MgCl~2~, 150 mM NaCl, 2 mM ATP. Efficiency of Rab8a phosphorylation was compared using PhosTag gel electrophoresis and immunoblotting with Rab8a-pT72 antibody ([Figure S1](#mmc1){ref-type="supplementary-material"}).

### Phosphorylation of Rab8a {#sec4.3.4}

Full length GST-MST3 produced in insect cells (DU30889) was obtained from MRC-PPU Reagents and Services (<https://mrcppureagents.dundee.ac.uk/reagents-proteins/overview>). Rab8a was incubated with GST-MST3 at molar ratios between 4:1 to 9:1 (substrate:enzyme). Typical concentrations of Rab8a were 1-3 mg/ml, while the concentration of MST3 was 1 mg/ml in a total volume between 2-15 ml. The buffer of the reaction was adjusted to 50 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl~2~ and 2 mM ATP, pH 7.5. The reaction mixture was incubated at room temperature overnight (12-18 hours). To separate pRab8a from the non-phosphorylated form, the reaction mixture was dialyzed against low-salt ion exchange buffer (10 mM MES, 10 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, pH 5.2) for two hours and then loaded onto a MonoS 5/50 GL column (GE Healthcare) equilibrated to the low-salt ion-exchange buffer. Elution of pRab8a was performed by running a 50% gradient from low- to high-salt buffer (10 mM MES, 1 M NaCl, 5 mM MgCl2, 1 mM DTT, pH 5.2) over 30 column volumes ([Figure S2](#mmc1){ref-type="supplementary-material"}). The phosphorylation of Rab8a~1-181~ was confirmed by PhosTag gel electrophoresis. In order to stabilize pRab8a, the pH was adjusted to pH 7.5 immediately after elution from the ion-exchange column.

### Crystallization, Data Collection and Refinement {#sec4.3.5}

Crystals of pRab8(Q67L): His~6~-RL2 complex were obtained in a 1:1 molar ratio of protein:peptide at a total of 12 mg/mL. Crystals were grown in 100 mM HEPES buffer (pH 7), 10% PEG4,000, and 10% 2-propanol. Plate-like crystals were harvested in precipitant supplemented with 25% glycerol and stored frozen in liquid nitrogen. X-ray data were collected under a cryogenic nitrogen stream at 100K (beamline 24-ID-C, Advanced Photon Source).

Native diffraction data were reduced using XDS and aimless, followed by structure determination using the Phaser software in the PHENIX package ([@bib1], [@bib27]). Initial rounds of molecular replacement using Rab8a \[GppNHp, PDB code [4lhw](pdb:4lhw){#intref0100}; ([@bib13])\] resulted in a solution for 2 molecules in the asymmetric unit. Following successful identification of Rab8a in the crystal lattice, the electron density for the coiled coil of the effector was apparent. Side chains for RILPL2 were clear in the initial electron density, and refinement was performed using multiple rounds of model building and energy minimization using PHENIX and COOT ([@bib7]). The asymmetric unit contains two molecules of Rab8a (A:4-176, B:2-176) bound to GTP and a magnesium ion, and two molecules of the effector (C:129-159, E:129-160). The hexahistidine tag at the N-termini of the effector is not seen in electron density maps, except for one histidine at the N-terminus of chain C. Comprehensive validation, including MolProbity, was performed during the refinement process to gauge the quality of the model ([@bib43]). Statistics of the data collection and refinement are shown in [Table 1](#tbl1){ref-type="table"}.

### Structural Analyses and Superpositions {#sec4.3.6}

In general, structures were aligned using the 'secondary structure matching' (SSM) protocol in COOT. The backbone superpositions of Rab8a from multiple structures (complexed, uncomplexed) typically aligned with an RMSD of 0.4 Å. The heterotetrameric structures of Rab8a:RILPL2 and Rab7:RILP were aligned using the Superpose software in CCP4 ([@bib23], [@bib44]). In order to better visualize the relative positions of the effectors, secondary structures from all 4 molecules in each complex were aligned. A total of 330 residues were matched, including 21 residues from each chain of RILP and RILPL2. The overall RMSD for the backbone atoms was approximately 3 Å.

### Pulldown Assays, Isothermal Titration Calorimetry, and Static Light Scattering {#sec4.3.7}

Calorimetry was performed in triplicate on an ITC-200 instrument (Malvern Panalytical). Protein concentrations were calculated based on their Abs~280~ using a ND-1000 NanoDrop spectrophotometer (Thermo Scientific). Following purification of Rab8a, the protein was dialyzed together in the same buffer as RILPL2 (10 mM Tris-HCl, 300 mM NaCl, 5 mM MgCl~2~, 20 mM imidazole and 1 mM DTT). Samples were centrifuged at 13,200 rpm for 10 minutes prior to concentration determination and ITC analysis. The concentrations of proteins for injections were between 400-600 μM (His~6~-RILPL2, residues 129-165) and 40-60 μM Rab8a and pRab8a (1-181).

For *in vitro* pulldowns, full-length RILPL2 (1-211) and the GTD of myosin Va (residues 1462-1853) were used. Rabs, RILPL2, and MyoVa (GTD) were mixed together in 1.5 mL centrifuge tubes at final concentrations ranging from 2.5-10 μM with 25 μl Ni^2+^- agarose resin in a final volume of 1ml of binding buffer (20 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole, 5 mM MgCl~2~, 10 mM β-mercapotoethanol). The reaction mixture was subjected to mild shaking for 15 minutes. Following gentle centrifugation (1,000 rpm), the resin was washed 3 times with 1 ml of the binding buffer. Following release of proteins from resin with 50 μl elution buffer (20 mM Tris-Cl pH 8.0, 300 mM NaCl, 200 mM imidazole), samples were subjected to SDS-PAGE and visualization with 0.5% Coomassie Brilliant Blue. Quantification of pulldowns was carried out using the Gel analyzer function of ImageJ([@bib34]), and statistical analyses were done using Microsoft Excel, version 15.28.

Static light scattering coupled to gel filtration was performed using a miniDAWN system (Wyatt Corp), an Optilab rEX refractometer, and a Superdex 200 (10/300) column. Full-length RILPL2 with an uncleaved polyhistidine tag was used, and 500μL was injected at a concentration of 1mg/mL. Data were processed using Astra software version 5.3.

### Plasmids for Cellular Assays {#sec4.3.8}

The plasmids used for co-immunoprecipitation experiments were acquired from MRC PPU Reagents and Services (<https://mrcppureagents.dundee.ac.uk/reagents-proteins/overview>): HA-empty pCVM5 (DU49303); GFP-empty pcDNA5 (DU13156); Flag-LRRK2 R1441G pCMV (DU13077); Flag-LRRK2 Y1699C pCMV (DU13165); HA-Rab8a WT pCMV (DU35414); HA-Rab10 WT pCMV (DU44250); RILPL2-GFP WT pcDNA5D FRT/TO (DU27481); RILPL2-GFP R130K pcDNA5D FRT/TO (DU68258), RILPL2-GFP R130A pcDNA5D FRT/TO (DU68022); RILPL2-GFP R130Q pcDNA5D FRT/TO (DU27521); RILPL2-GFP R130E pcDNA5D FRT/TO (DU27520); RILPL2-GFP P131A pcDNA5D FRT/TO (DU68030); RILPL2-GFP P131C pcDNA5D FRT/TO (DU68031); RILPL2-GFP P131K pcDNA5D FRT/TO (DU68256), RILPL2-GFP P131R pcDNA5D FRT/TO (DU68257) RILPL2-GFP R132K pcDNA5D FRT/TO (DU68023); RILPL2-GFP R132A pcDNA5D FRT/TO (DU67110); RILPL2-GFP R132Q pcDNA5D FRT/TO (DU68037); RILPL2-GFP R132E pcDNA5D FRT/TO (DU27522); RILPL2-GFP F133A pcDNA5D FRT/TO (DU68033); RILPL2-GFP L135A pcDNA5D FRT/TO (DU68032); RILPL2-GFP R139A pcDNA5D FRT/TO (DU68025); RILPL2-GFP R139Q pcDNA5D FRT/TO (DU68024); RILPL2-GFP R139E pcDNA5D FRT/TO (DU68026); RILPL2-GFP K149A pcDNA5D FRT/TO (DU68029); RILPL2-GFP K149Q pcDNA5D FRT/TO (DU68027); RILPL2-GFP K149E pcDNA5D FRT/TO (DU68028); RILPL2-GFP E157A pcDNA5D FRT/TO (DU68036); RILPL2-GFP E157Q pcDNA5D FRT/TO (DU68034); RILPL2-GFP E157K pcDNA5D FRT/TO (DU68035), HA-Rab8a Q67L pCMV (DU39393), HA-Rab8a T22N pCMV (DU39392), HA-Rab8a T4A pCMV5 DU68045), HA-Rab8a D44A pCMV5 (DU68041), HA-Rab8a D44N pCMV5 (DU68039), HA-Rab8a D44K pCMV5 (DU68040), HA-Rab8a K58A pCMV5 (DU68044), HA-Rab8a K58Q pCMV5 (DU68042), HA-Rab8a K58E (DU68043), JIP3-GFP pcDNA5D FRT/TO (DU27721), JIP4-GFP pcDNA5D FRT/TO (DU27684), RILPL1-GFP pcDNA5D FRT/TO (DU27305).

### Antibody Reagents {#sec4.3.9}

Antibodies used in this study were diluted in 5% w/v bovine serum albumin in TBS supplemented with 0.1% Tween-20 and 0.03% w/v sodium azide. The Rabbit monoclonal antibody for total LRRK2 (N-terminus) was purified at the University of Dundee ([@bib6]). Anti-GFP (PABG1, Chromotek, used at 1:1000) anti-GFP (\#2956, CST, used at 1:1000), anti-HA (3F10, Merck, used at 1:1000), anti-pT72-Rab8a (MJF-R20, Abcam, used at 0.5 μg/mL), anti-LRRK2 C-terminal (N241A/34, Neuromab, used at 1:1000), and anti-αTubulin (3873S, CST, used at 1:5000), anti-GAPDH (\#sc-32233, Santa Cruz Biotechnology, used at 1:5000). Secondary antibodies used were Licor IRDye for 800CW goat anti-rabbit (925-32211), goat anti-mouse (926-32210) and 680LT goat anti-rat (925-68029) and goat anti-mouse (926-68020), all used at 1:10,000 dilution in TBS with 0.1% v/v Tween-20 (TBS-T) and horseradish peroxidase-conjugated rat IgG secondary antibody (\#31470, Thermo Fisher Scientific) used at 1:10,000 dilution in 5% non-fat dry milk dissolved in TBS-T.

### Culture and Transfection of Cells {#sec4.3.10}

HEK293 cells were cultured in Dulbecco's modified Eagle medium (Glutamax, Gibco) supplemented with 10% fetal bovine serum (FBS, Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin. Transient transfections were performed 40-48 hr prior to cell lysis using polyethylenimine PEI (Polysciences) at around 60-70% confluence. Transfections for co-immunoprecipitation experiments were done in 10 cm round cell culture dishes using 3 μg of Flag-LRRK2 R1441G or Flag-LRRK2 Y1699C as indicated, 1 μg of HA control or HA-Rab8a or HA-Rab10 and 1 μg of GFP control, RILPL2-GFP or JIP3/4-GFP cDNA construct per dish diluted in 1 mL of OPTIMEM media and supplemented with 20 μg of PEI and incubated for 20 min before being added to the cell media. 1 h before lysis cells were treated with 500 nM of MLI-2 inhibitor or 0.1% DMSO control. Lysates were clarified by centrifugation at 17,000 x *g* for 10 min.

### Co-Immunoprecipitation of Rab GTPases and RILPL2, JIP3 and JIP4 {#sec4.3.11}

Cells were washed with PBS and lysed in lysis buffer - 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 10 mM sodium β-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate^∗^10H~2~O, 0.27 M sucrose and supplemented fresh before lysis with 1% v/v Triton-x100, 1 tablet of cOmplete Mini (EDTA-free) protease inhibitor (Merck, 11836170001) per 10 mL of buffer, 0.1 μg/mL of microcystin and 1 μM of sodium orthovanadate.

For GFP immunoprecipitation, lysates were incubated with nanobody αGFP binder sepharose from MRC PPU Reagents and Services for 1 hr (15 μl of packed resin/0.5 mg of lysate). Bound complexes were recovered by washing the beads three times with wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) before eluting with 2xSDS/PAGE sample buffer supplemented with 1% v/v 2-mercaptoethanol. The samples were denatured at 70°C for 10 min and the resin was separated from the sample by centrifugation through a 0.22 μm Spinex column (CLS8161, Sigma).

### Gel Electrophoresis and Immunoblot Analysis {#sec4.3.12}

Samples were run on gels consisting of a 4% w/v acrylamide stacking gel \[4% w/v acrylamide, 0.125 M Tris-HCl pH 6.8, 0.2% v/v Tetramethylethylenediamine (TEMED) and 0.08% w/v ammonium persulphate (APS)\] and 10% w/v acrylamide separating gel \[10% w/v acrylamide, 0.375 M Bis-Tris pH 6.8, 1% v/v tetramethylethylenediamine (TEMED) and 0.05% w/v ammonium persulphate (APS)\] in MOPS buffer (50 mM MOPS, 50 mM Tris, 1 mM EDTA, 0.1% w/v SDS) at 90-120 V. For Coomassie staining, gels were stained with InstantBlue™ Ultrafast Protein Stain (ISB1L, Sigma-Aldrich) according to the manufacturer\'s instructions and the gels were imaged using LICOR Odyssey CLx. For immunoblot analysis, proteins were electrophoretically transferred onto nitrocellulose membranes (Amersham Protran 0.45 μm NC; GE Healthcare) at 90 V for 90 min on ice in transfer buffer \[48 mM Tris/HCl, 39 mM glycine, 20% v/v methanol\]. Transferred membranes were blocked with 5% w/v non-fat dry milk dissolved in TBS-T \[20 mM Tris/HCl, pH 7.5, 150 mM NaCl and 0.1% v/v Tween 20\] at room temperature for 1 h. Membranes were then incubated with primary antibodies overnight at 4°C. After washing membranes in TBS-T 3x15 min, membranes were incubated with secondary antibodies at room temperature for 1 h. After washing membranes in TBS-T 3x15 min membranes were scanned using LICOR Odyssey CLx.

### PhosTag Gel Electrophoresis and Immunoblot Analysis {#sec4.3.13}

Samples were supplemented with 10 mM MnCl~2~ before loading gels. Gels for Phos-tag SDS/PAGE consisted of a stacking gel \[4% w/v acrylamide, 0.125 M Tris/HCl, pH 6.8, 0.2% v/v tetramethylethylenediamine (TEMED) and 0.08% w/v ammonium persulfate APS\] and a separating gel \[10% w/v acrylamide, 375 mM Tris/HCl, pH 8.8, 75 μM PhosTag reagent (MRC PPU Reagents and Services), 150 μM MnCl~2~, 0.1% v/v TEMED and 0.05% w/v APS\]. After centrifugation at 17,000 x g for 1 min, samples were loaded and electrophoresed at 90 V with the running buffer \[25 mM Tris/HCl, 192 mM glycine and 0.1% w/v SDS\]. For Coomassie staining, gels were stained with InstantBlue™ Ultrafast Protein Stain (ISB1L, Sigma-Aldrich) according to the manufacturer\'s instructions and the gels were imaged using LICOR Odyssey CLx. For immunoblot analysis, gels were washed 3x10 min in 48 mM Tris/HCl, 39 mM glycine, 10 mM EDTA and 0.05% w/v SDS followed by one wash in 48 mM Tris/HCl, 39 mM glycine and 0.05% w/v SDS for 10 min. Proteins were electrophoretically transferred onto nitrocellulose membranes (Amersham Protran 0.45 μm NC; GE Healthcare) at 100 V for 180 min on ice in transfer buffer \[48 mM Tris/HCl, 39 mM glycine, 20% v/v methanol\]. Transferred membranes were blocked with 5% w/v non-fat dry milk dissolved in TBS-T \[20 mM Tris/HCl, pH 7.5, 150 mM NaCl and 0.1% v/v Tween 20\] at room temperature for 1 h. Membranes were then incubated with primary antibodies overnight at 4°C. After washing membranes in TBS-T 3x15 min, membranes were incubated with horseradish peroxidase labelled secondary antibody diluted in 5% skimmed milk powder in TBS-T at room temperature for 1 h. After washing membranes in TBS-T (5x10 mins), protein bands were detected by exposing films (Amersham Hyperfilm ECL, GE Healthcare) to the membranes using an ECL solution (SuperSignal West Dura Extended Duration, Thermo Fisher Scientific).

Data and Code Availability {#sec4.4}
--------------------------

The coordinates for the structure of the pRab8a:RILPL2 complex have been deposited in the Protein Data Bank with accession code [6RIR](pdb:6RIR){#intref0110}. PDB codes [4LHW](pdb:4LHW){#intref0115}, [4KP3](pdb:4KP3){#intref0120}, and [1YHN](pdb:1YHN){#intref0125} were referenced in this study.
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